Document:

EMPLOYMENT AGREEMENT

         EMPLOYMENT AGREEMENT dated as of December 1, 2004, by and between
QMEDCARE, INC., a Delaware corporation (the "Company"), with offices at 25
Christopher Way, Eatontown, New Jersey 07724 and JOHN W. ROHFRITCH
("Executive"), with an address at 21 Church Street, Farmington, CT 06032.

         NOW THEREFORE, in consideration of the premises and the mutual
covenants contained in this Agreement, it is agreed between Company and
Executive as follows:

1. EMPLOYMENT.

         Subject to the terms and conditions hereof, Company hereby employs
Executive as its President, during the term hereof, as hereinafter described,
and Executive hereby accepts such employment.

2. EFFECTIVE DATE.

         This Agreement shall become effective March 1, 2005.

3. TERM OF EMPLOYMENT.

         Unless earlier terminated pursuant to Section 8 hereof, the term of
employment under this Agreement shall be for a one-year period commencing on the
Effective Date and ending one year later, on February 28, 2006 (the "Term").
(The last day of the Term is the "Expiration Date".) This Agreement shall be
automatically renewed for successive one (1) year periods unless either party
shall notify the other in writing of its intention not to renew this Agreement
("Non-renewal Notice"), which Non-renewal Notice shall be given at least 90 days
prior to the end of the then current term.

4. DUTIES.

         4.1 During the Term of his employment by Company, Executive shall serve
as President of the Company. In Executive's capacity as President of QMedCare,
Executive shall have the customary powers, responsibilities and authorities of
presidents and chief executive officers of corporations of the nature of
QMedCare, as it exists from time to time, including primary responsibility for
the day-to-day management of QMedCare's affairs and its operations, any duties
prescribed for such positions in the By-laws of QMedCare as in effect from time
to time, and those responsibilities and duties as the Board of Directors may
from time to time direct Executive to undertake and to perform which are
consistent and appropriate to the capacities of senior corporate management held
by Executive. Executive shall be under the oversight of, shall answer to, and
shall take direction from, the Board of Directors of QMedCare. Executive shall
also comply with the personnel policies established by Company, and, to the
extent made applicable to Company, by Company's corporate parent, QMed, Inc.

         4.2 Executive, if elected, shall serve as a member of the Board of
Directors of QMedCare.

         4.3 Executive shall serve QMedCare faithfully and to the best of his
ability and shall devote his full duty of loyalty, and his full time, skill,
efforts and attention during business hours (unless prevented by illness or
incapacitation) to the business affairs of QMedCare.

         4.4 As long as the Board of Directors has not reasonably determined
that such activities interfere with his duties and responsibilities hereunder,
nothing in this Agreement shall preclude Executive from engaging in charitable
and community affairs, and from managing any passive investment made by him in
publicly traded securities or other property. Executive may serve as a member of
the boards of directors or as a trustee of any other corporation, association or
entity, so long as in the reasonable judgment of Executive and of the Board of
Directors of the Company, such activities do not conflict or interfere with
Executive's duties and responsibilities hereunder.

<PAGE>

5. COMPENSATION.

         5.1 Salary. Company shall pay Executive a base salary ("Base Salary")
of $180,000 for the Term. Base Salary shall be payable in accordance with the
ordinary payroll practices of Company.

         5.2 Bonuses.

                  (a) In addition to Base Salary, Company shall establish bonus
targets based on enrollment and Company's audited profit and loss statement
generated for the Term, under which Executive will be eligible for a bonus in an
amount up to 35% of his salary, as well as stock options pursuant to paragraph
5.4 below (the "Target Bonus"). The determination of what portion of the Target
Bonus shall have been earned by the Executive shall be made by the Executive
Compensation Committee of the Board of Directors.

                  (b) Executive's bonus, if any, will be paid no later than
________________.

         5.3 Compensation Plans and Programs. Executive shall be eligible to
participate in any compensation plan or program, annual or long term, maintained
by Company in which other senior executives of Company participate, on terms
which are comparable to those applicable to such other senior executives.

         5.4 Stock Option Awards. Upon the effective date of this agreement,
Executive will be granted an option (the "Option") for 10,000 shares of the
common stock of the Company's corporate parent, QMed, Inc. pursuant to the
QMed's stock option plan. Such options shall vest on the ninth anniversary date
of the grant, provided, however, acceleration of vesting shall occur for
one-third of the grant on the 1st, 2nd and 3rd anniversary date of the grant if
the Executive has met the full Target Bonus, established under paragraph 5.2(a)
above, for that respective year.

6. BENEFITS

         6.1 Benefit Programs. Executive shall be eligible to participate in the
medical, disability, dental and vision programs of Company from time to time in
effect and generally available to Company's senior executives. The standard
employee contribution for such program(s) shall be borne by Company.

         6.2 Vacation. Executive is entitled to three weeks (15 Business days)
of paid vacation each Calendar year. Executive shall not utilize his vacation
time in periods of longer than 10 consecutive business days without obtaining
the express consent of the CEO. Unused vacation shall be forfeited as of
December 31 of each calendar year. In addition to vacation time, the Executive
will be paid for sick, personal and floating days up to a maximum of nine days
per calendar year. Any of that time not taken will be forfeited for that year.

         6.3 Expenses. Executive is authorized to incur reasonable expenses in
carrying out his duties and responsibilities under this Agreement, including,
without limitation, expenses for travel, cellular telephone (including access
charges and business calls) and similar items related to such duties and
responsibilities. Company will reimburse Executive for all such expenses upon
presentation by Executive of itemized accounts of such expenditures, in
accordance with the procedures for reimbursement established by the Company.
Company shall also reimburse Executive for up to $25,000 in relocation expenses
upon presentation by Executive of satisfactory documentation of such expenses.

         6.4 Automobile. Company shall pay Executive for all reasonable expenses
(including, but not limited to, lease payments, liability insurance and fuel
costs), of up to $500 per month incurred in operating an automobile for
Executive's use in the performance of his duties hereunder and in the conduct of
Company's affairs.

<PAGE>

7. INDEMNIFICATION.

         Executive shall be indemnified by Company against expenses, including
attorneys' fees, actually and necessarily incurred by him in connection with the
defense of any action, suit, investigation or proceeding or similar legal
activity, regardless of whether criminal, civil, administrative or investigative
in nature ("Claim"), to which he is made a party or is otherwise subject to, by
reason of his being or having been an officer, employee, director or agent of
Company, to the full extent permitted by applicable law and the Certificate of
Incorporation of Company. Such right of indemnification is in addition to and
not exclusive of any other rights to which Executive may be entitled under:
Company's Certificate of Incorporation or By-laws, as in effect from time to
time, any agreement or otherwise.

8. TERMINATION OF EMPLOYMENT.

         8.1      Termination Without Cause or for Good Reason.

         (a)      Company may terminate Executive's employment at any time for
                  any reason. If Executive's employment is terminated effective
                  prior to the Expiration Date: (I) by Company other than (i)
                  for Cause (as defined in Section 8.4 hereof), or (ii) as a
                  result of Executive's death or Permanent Disability (as
                  defined in Section 8.2 hereof); or (II) by Executive for Good
                  Reason (as defined in Section 8.1 (b) hereof), Executive shall
                  receive or commence receiving as soon as practicable in
                  accordance with the terms of this Agreement:

                  (i)      such payments under applicable plans or programs,
                           including but not limited to those referred to in
                           Section 5.3 hereof, to which he is entitled pursuant
                           to the terms of such plans or programs through the
                           date of termination;

                  (ii)     any earned but unpaid bonus which amount shall be
                           paid in a cash lump sum within thirty (30) days of
                           the date of termination; and

                  (iii)    payment in respect of accrued but unused vacation
                           days (the "Vacation Payment") and compensation earned
                           but not yet paid (the "Compensation Payment") which
                           amount shall be paid in a cash lump sum within thirty
                           (30) days of the date of termination.

                  (iv)     severance payment of six months salary which amount
                           shall be paid in a cash lump sum within (30) days of
                           the date of termination.

         (b)      For purposes of this Agreement, "Good Reason" shall mean any
                  of the following (unless done with Executive's express prior
                  written consent):

                  (i)      Any material breach by Company of any provision of
                           this Agreement, including, without limitation, any
                           material reduction by Company of Executive's duties
                           or responsibilities (except in connection with the
                           termination of Executive's employment for Cause, as a
                           result of Permanent Disability, as a result of
                           Executive's death or by Executive other than for Good
                           Reason);

                  (ii)     Any reduction by Company in Executive's Base Salary;

<PAGE>

                  (iii)    The failure by Company to obtain the specific
                           assumption of this Agreement by any successor or
                           assign of Company as provided for in Section 11
                           hereof;

                  (iv)     8.2 Permanent Disability. If Executive becomes
                           totally and permanently disabled (as defined in
                           Company's disability benefit plan applicable to
                           senior executive officers as in effect on the date
                           thereof) ("Permanent Disability"), Company or
                           Executive may terminate Executive's employment on
                           written notice thereof, and Executive shall receive
                           or commence receiving, as soon as practicable:

                           (i)      amounts payable pursuant to the terms of the
                                    disability insurance policy or similar
                                    arrangement, which Company maintains during
                                    the Term;

                           (ii)     the Vacation Payment and the Compensation
                                    Payment which shall be paid to Executive as
                                    a cash lump sum within 30 days of such
                                    termination; and

                           (iii)    such payments under applicable plans or
                                    programs, including but not limited to those
                                    referred to in Section 5.3 hereof, to which
                                    he is entitled pursuant to the terms of such
                                    plans or programs through the date of
                                    termination.

         8.3 Death. In the event of Executive's death during the Term,
Executive's estate or designated beneficiaries shall receive or commence
receiving, as soon as practicable in accordance with the terms of this
Agreement:

                  (i)      any death benefits provided under the executive
                           benefit programs, plans and practices referred to in
                           Sections 5.3 and 6.1 hereof, in accordance with their
                           respective terms; and

                  (ii)     such other payments under applicable plans or
                           programs, including but not limited to those referred
                           to in Section 5.3 hereof, to which Executive's estate
                           or designated beneficiaries are entitled pursuant to
                           the terms of such plans or programs.

         8.4 Voluntary Termination by Executive: Discharge for Cause. Company
shall have the right to terminate the employment of Executive for Cause (as
hereinafter defined). In the event that Executive's employment is terminated by
Company for Cause, as hereinafter defined, or by Executive other than for Good
Reason or other than as a result of the Executive's Permanent Disability or
death, prior to the Expiration Date, Executive shall be entitled only to
receive, as a cash lump sum within 30 days of such termination the Compensation
Payment and the Vacation Payment. As used herein, the term "Cause" shall be
limited to (i) willful malfeasance, willful misconduct or gross negligence by
Executive in connection with his employment in a matter of material importance
to the conduct of Company's affairs which has a material adverse affect on the

<PAGE>

business of Company, (ii) continuing refusal by Executive to perform his duties
hereunder, as defined by the Board of Directors of the Company, which continues
for thirty (30) days after notice of any such refusal to perform such duties or
directions as given to Executive by the Board of Directors, (iii) any material
breach of this Agreement by Executive, which continues for thirty (30) days
after notice of any such material breach is given to Executive by the Board of
Directors, (iv) conduct which, in the reasonable business judgment of the Board
of Directors, tends to damage the reputation or good will of the Company and/or
its corporate affiliates, or would tend to damage such reputation or good will
were Executive to remain associated with Company; or (v) the indictment or
conviction of Executive for commission of a crime. For purposes of this
subsection, no act or failure to act on the Executive's part shall be considered
"willful" unless done, or omitted to be done, by the Executive, not in good
faith and without reasonable belief that his action or omission was in the best
interest of Company. Termination of Executive pursuant to this Section 8.4 shall
be made by delivery to Executive of a copy of a resolution duly adopted by the
affirmative vote of the majority of the members of the Board of Directors called
and held for such purpose (after 30 days prior written notice to Executive and
reasonable opportunity for Executive to be heard before the Board of Directors
prior to such vote), finding that in the good faith business judgment of such
Board of Directors, Executive had engaged in conduct as set forth in any of
clauses (i) through (v) above and specifying the particulars thereof.

9. RESTRICTIVE COVENANTS AND OTHER PROVISIONS.

         9.1 Confidentiality. Executive recognizes that, by reason of his
employment hereunder, he may acquire confidential information and trade secrets
concerning the operation of Company, and/or affiliated companies, corporate
affiliates, and/or business partners of the Company, the use or disclosure of
which could cause Company and/or Company's corporate affiliates, substantial
loss and damages which could not be readily calculated and for which no remedy
at law would be adequate. Accordingly, Executive covenants and agrees that he
will not, during and/or after the Term, disclose, furnish, use except on behalf
of the Company and its affiliates, and/or make accessible to any person, firm or
corporation (except (i) in the ordinary course of business in performance of
Executive's obligations hereunder or (ii) when required to do so by law or (iii)
with the prior written consent of Company pursuant to authority granted by a
resolution of the Board of Directors), any confidential information that
Executive has learned or may learn by reason of his association with Company
and/or its affiliates (including QMed, Inc.), and/or in the performance of his
obligations hereunder. As used herein, the term "confidential information" shall
include, without limitation, information not generally disclosed to the public,
or to the trade generally, by the Company and/or its affiliates (including QMed,
Inc.), with respect to the business or affairs of Company and/or its affiliates,
customers, corporate parents, or other business associates, including, without
limitation, information relating to business opportunities, customer lists,
price lists, solicitations, customers, transactions, work in progress, trade
secrets, systems, techniques, procedures, methods, inventions, facilities,
financial information, business plans or prospects.

         9.2 Non-Competition. During the period of his employment hereunder, and
for one year thereafter, Executive agrees that, without the prior written
consent of Company: (A) he will not, directly or indirectly, either as
principal, manager, agent, consultant, officer, employee, stockholder, partner,
investor, lender or executive, or in any other capacity, carry on, be engaged in
or have any financial interest in, or assist, any business which is in
competition with the business of Company and/or its corporate affiliates
(including QMed, Inc.), and (B) he shall not, on his own behalf or on behalf of
any person, firm or company, directly or indirectly, solicit or offer employment
to any person who is an employee of the Company or of any of the Company's
corporate affiliates (including QMed, Inc.).

<PAGE>

10. INJUNCTIVE RELIEF.

         Without intending to limit the remedies available to Company, Executive
acknowledges that a breach of the covenants contained in Section 9 of this
Agreement may result in material irreparable injury to Company and/or its
affiliates, for which there is no adequate remedy at law, that it will not be
possible to measure damages for such injuries precisely and that, in the event
of such a breach or threat thereof, Company shall be entitled to obtain a
temporary restraining order and/or a preliminary or permanent injunction
restraining Executive from engaging in activities prohibited by such Section or
such other relief as may be required to specifically enforce any of the
covenants in such Section. This relief shall be awarded to the Company in
addition to any damages which it may also recover as a result of the breach or
otherwise.

11. ASSIGNMENT.

         This contract shall be binding upon and inure to the benefit of the
heirs and representatives of Executive and the assigns and successors of
Company. Neither this Agreement, nor any rights or obligations hereunder, shall
be assignable or otherwise subject to hypothecation by Executive (except by will
or by operation of the laws of intestate succession). Company may assign this
Agreement and/or its rights and obligations hereunder, to any successor in
interest (whether by merger, purchase or otherwise) or other entity.

12. NOTICES.

         Any notice required or permitted to be given under this Agreement shall
be in writing and shall be deemed sufficiently given if delivered in person, or
mailed by certified first class mail, postage prepaid, or sent by a reputable
overnight courier service, addressed to the party to be notified at the
address(es) specified below (or such other address as may be specified by notice
in this manner):

         Notice to Company:

                  QMedCare, Inc.
                  25 Christopher Way
                  Eatontown, NJ 07724

                  Attention: Board of Directors; Jane Murray, Director

         Notice to Executive:

                  John W. Rohfritch
                  21 Church Street__________________
                  Farmington, CT 06032__________________

         Notices shall be deemed given as of the date delivered or the date
entrusted to the United States postal service or courier service, provided that
delivery to the recipient actually occurs.

13. COUNTERPARTS.

         This Agreement may be executed in one or more counterparts, each of
which shall be an original and all of which shall constitute but one and the
same instrument.

15. HEADINGS.

         The headings in this Agreement are for convenience only and in no way
define, limit, or describe the scope or intent of any provision of this
Agreement.

<PAGE>

16. WAIVER.

         The waiver by either party of noncompliance by the other party of any
term or provision of this Agreement shall not be construed as a waiver of any
other non-compliance.

17. ARBITRATION.

         In the event a dispute arises under any term or provision hereof, such
dispute shall be settled by arbitration in the State of New Jersey, by and in
accordance with the rules then existing of the Center for Dispute Resolution or
of the American Arbitration Association.

18. SEVERABILITY.

         If any one or more of the provisions contained in this Agreement shall
be held to be invalid, illegal, or unenforceable in any respect, such
invalidity, illegality, or unenforceability shall not affect any other
provisions hereof.

19. GOVERNING LAW.

         THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF NEW JERSEY WITHOUT REGARD TO ITS CONFLICTS OF LAWS
RULES OR PRINCIPLES.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.

                                     QMEDCARE, INC.

                                      By: /s/ Jane Murray
                                         ---------------------------------------
                                         Jane Murray, Executive Vice President,
                                         QMed, Inc., Director, QMEDCARE, INC.

                                      EXECUTIVE

                                       /s/ John W. Rohfritch
                                      -----------------------------------
                                      John W. RohfritchExhibit 10.1

                                    AGREEMENT

         This Agreement (the "Agreement") is made and entered into effective
March 1, 2005 (the "Effective Date"), by and among American Consolidated
Management Group, Inc., a Utah corporation with its principal offices at 714
Fairview Road, Greenville, SC 29651 ("Company"). and Nu Specialty Foods Group,
L.L.C., a North Carolina limited liability company ("Vendor"), with its
principal offices at P.O. Box 1179, Graham, N.C. 27253.

                                    RECITALS

         A. Company owns a technology, in the geographical area covered by this
Agreement, which technology concerns the prevention of the degradation of
vitamins and nutrients contained within fruits and vegetables during and
following their dehydration and/or freeze-drying, which technology is defined
hereinbelow, and owns the trademark term "Sunutra(TM)" for utilization with
products produced by this technology; and,

         B. Vendor desires to purchase the compound produced from the subject
technology from the Company, and to produce, manufacture and market frozen
unbaked biscuit dough, frozen baked biscuits, and dry mixes and blends of
biscuits [hereinafter collectively referred to as the "Products"] which Products
will incorporate the natural dry compound covered by the trademark known as
"Sunutra(TM)," and which compounds shall generally be referred to throughout
this Agreement as "Sunutra(TM)."

         NOW, THEREFORE, in consideration of the premises and the respective
representations, warranties, covenants and agreements contained herein, the
parties hereto hereby agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

         For purposes of this Agreement, the term:

         "Licensed Patent" means the patent application filed in the United
States Patent Office on December 20, 2004, under serial number 11/015651,
including all divisions, continuations and reissues thereof, as well as all
additional applications, amendments and supplements filed by, or on behalf of
the Company. This term specifically covers all applications by the original
inventor Jack Watkins, and/or any collaborator thereof, including those that may
have yet to be filed with the U.S. Patent Office.

         "Products" means frozen unbaked biscuit dough, frozen baked biscuits,
and biscuit-mix dry.

         "Licensed Trademarks" means the "Sunutra(TM)", said term being
registered with the United States Patent and Trademark Office, on March 29, 2004
under serial number 78392304.

         "Contract Territory" means the United States of America.

         "Technology" means the technology currently owned by the Company which
produces a natural dry compound that molecularly adheres to food particles and
acts as a partition barrier from heat and degradation to micronutrients and
phytochemicals enabling such natural dry compound to be applied to both wet and
dry processed foods, and includes any future developments, improvements,
additions and inventions hereafter made to this Technology which may occur
throughout the duration and utilization of the Technology, and which includes
the Licensed Patent, and any and all subsequent patents obtained by the Company
.. This definition and this Agreement is specifically limited to applications of
this technology in processed foods.

         "Related Agreements" means the Confidentiality Agreement and Materials
Transfer Agreement between the parties hereto.

<PAGE>

                                   ARTICLE II

                        LICENSES AND PRODUCT COMMITMENTS

2.1. Marketing Rights.

         For the time period to be agreed upon between the parties, the Company
grants to Vendor the sole and exclusive right to market, distribute and sell the
Technology for utilization in the Products in the Contract Territory for a
period of three (3) years, beginning on January 1, 2006; provided that initial
purchase set out hereinbelow is fully consummated. Vendor may extend this period
of exclusivity for an additional two (2) year period; provided, that Vendor
shall comply with the minimum volumes set out herein below. In consideration for
this exclusivity, Vendor shall purchase and pay for 1,586 pounds of the Sunutra
blend agreed upon, on, or before June 1, 2005. It is further agreed and
understood that in the event that through the fault of the Company, Vendor has
not obtained its selected blend of Sunutra(TM), then in that event, Vendor's
obligation to purchase the aforesaid 1,568 pounds of Sunutra(TM) shall be
suspended until such time as Vendor obtains its selected blend. Notwithstanding
anything herein to the contrary, all exclusivity rights granted in this
Agreement are specially limited to sales into the Food Service Segment of the
Food Industry.

2.2. Fixed Purchase Price.

         During the first two (2) years of this Agreement, Company shall timely
manufacture and deliver to Vendor all quantities of Sunutra(TM) and any other
natural dry compounds derived from the Technology required by Vendor at a price
of $68.00 per pound FOB, Poway, California, or any other point of delivery/sale
established by Company.

2.3. Licenses for Vendor re Trademarks and Patents. Throughout the term of this
Agreement, the Company grant to Vendor a license [as defined herein] to make,
use and sell the Technology for utilization in the Products under the Licensed
Trademarks throughout the Contract Territory on a royalty free basis. Vendor
shall have the right to use the Licensed Trademark, and to direct the
advertising, promoting, distributing and marketing of the Products, but only in
such manner as is reasonably calculated to maintain a high level of quality of
the goods manufactured and sold under the Licensed Trademark to protect
Company's proprietary interest in the Licensed Trademark. All labels, designs,
descriptive materials, promotional materials and advertising of any kind or
nature which includes the use of the Licensed Trademark shall be developed by
Vendor at its expense, but shall be subject to Company's prior approval, which
approval shall not be unreasonably withheld. The parties expressly agree that
Vendor shall not have any right, title or interest in the Licensed Trademark, or
Licensed Patent, except the right to use them in connection with the activities
of Vendor as set forth herein. Vendor agrees not to use the Licensed Trademark
or Licensed Patent other than as authorized hereunder without the prior written
consent of Company. Vendor agrees to terminate the use of the Licensed Trademark
and Licensed Patent upon the termination of this Agreement. Vendor agrees to
give adequate notice to the public that the Licensed Products are manufactured
under license, and Vendor agrees to provide legends on all Products or
containers for the Products with the legend "Patented," and/or "Patent Pending,"
as the case may be, together with the number of the Licensed Patents, and/or
Patent Pending, as the case may be from time to time. In any event, and
notwithstanding anything herein to the contrary, it is agreed and understood
that with regard to any products utilizing Sunutra(TM) will possess the
Sunutra(TM) brand logo visibly noticeable on the front of all retail packaging.
Notwithstanding anything herein to the contrary, it is specifically agreed and
understood that all packaging for the Products, and the uses of the Sunutra(TM)
logo shall be approved by the Company prior to the commercialization of any such
products. This prohibition includes any advertising conducted by customers of
Vendor in connection with any biscuit product sold by said customer(s).

<PAGE>

2.4 Order and Payment Terms. All orders placed by Vendor shall be completed by
Company in a timely manner that meets the delivery requirements of Vendor, and
Company shall expend its best efforts to deliver regular, uniform quantities of
Sunutra(TM) and any related compounds so ordered. For purposes of this
Agreement, orders of Sunutra(TM) and related compounds shall not be deemed to be
accepted unless they are manufactured to Vendor's requirements, as the case may
be, suitable for market, and meet all quality control standards and tests which
may reasonably be required by Vendor. In this regard, the Company and Vendor
shall work together to develop each blend of Sunutra(TM) to meet Vendor's needs
and requirements, it being understood that each product to be supplied may
require a unique blend of fruits and/or vegetables. From time to time during the
term of this Agreement, Vendor shall submit purchase orders to Company for
Sunutra(TM) and the other compounds derived from the Technology, subject to the
terms and conditions set forth in the purchase order form to be mutually agreed
to by the parties hereto.

2.5 Product Liability Insurance. Company shall provide, at its expense, product
liability insurance for the Sunutra(TM) blends and Technology in an amount and
scope satisfactory to Vendor throughout the term of this Agreement, and Company
shall cause Vendor to be named as a co-insured on such policy or policies
throughout the term of this Agreement.

2.6 Sales Requirements and Renewal Term. Vendor shall be required to meet
minimum purchase requirements as follows: For the year July, 2005 through June
30, 2006, a minimum purchase of 2,586 pounds of Sunutra blend; for July 1, 2006
through June 30, 2007, a minimum purchase of 13,063 pounds of Sunutra blend, and
for July 1, 2007 through June 30, 2008, a minimum purchase of 28,739 pounds of
Sunutra blend.

         Notwithstanding anything herein to the contrary, if Vendor fails to
meet the minimum purchase requirements then the exclusive rights granted herein
shall automatically expire and all rights shall become non-exclusive. In the
event that any exclusive rights shall terminate, then all subsequent sales shall
continue to be governed by the other terms and conditions of this Agreement. The
only penalty to Vendor for failure to meet these minimum purchases shall be the
loss of exclusivity as set out herein.

2.7 Confidentiality and Proprietary Info. Vendor and the Company shall not in
any time or in any manner, either directly or indirectly, divulge, disclose or
communicate to any person, firm, company or business, any information concerning
any matters affecting or relating to the business of Vendor, and the Company,
their respective manner of operation, methods of production, their plans,
processes, procedures, marketing strategies, contracts, customer lists, or other
data used in performing its obligations under this Agreement. The parties hereby
stipulate and agree that as between them, all such information of the Company
and Vendor is confidential and proprietary, and materially affects the
successful operation of Company's and Vendor's business and the preservation of
the Company's and Vendor's good will.

2.8 Continuing FDA and Regulatory Compliance by the Company. Throughout the term
of this Agreement, the Company at its expense, shall comply with any and all
governmental regulations relating to Sunutra(TM) and the Technology. Likewise,
Vendor shall fully comply with said rules and regulations, with the Company
assisting Vendor in any reasonable manner to insure said compliance with any
labeling requirements.

<PAGE>

2.9 Covenant of Vendor Not to Reserve Engineer Sunutra. Vendor understands and
agrees that Sunutra(TM), the Technology and the Licensed Patents as well and any
other technology contemplated by this Agreement is a proprietary right(s) owned
by the Company, and that Vendor does not possess, nor shall it possess or won
any right(s) in such technologies and rights, except as may be expressly set out
in this Agreement. All such matters are trade secrets of the Company. Vendor
covenants and agrees that it shall not, either directly, or indirectly, make any
attempt to reverse engineer any matter or technology covered by this Agreement,
or any effort to determine the formula, recipe, processes, applications, and/or
any other aspect of the Technology, Licensed Patents, or other similar matters,
nor shall Vendor knowingly permit any third party to undertake any similar
actions; provided, that Vendor may, at its own expense test, or have a third
party test any of the Products solely for their nutrient values and contents.
The provisions of this section 2.9 shall survive the termination of this
Agreement. Vendor furthermore understands and agrees that the maintenance and
strict adherence to the terms of this section 2.9 is critical to the viability
of the Company, and is the single most critical provisions of this Agreement;
such that, any breach of this section 2.9 cannot be adequately addressed by
monetary determination; therefore, the Company shall be entitled to injunctive
relief, without bond, in the event of any such breach(es), and that upon the
issuance of injunctive relief, the Company shall also be entitled to a judgment
against Vendor for the Company's reasonable costs and attorney fees incurred in
the seeking and obtaining of such relief, as determined by the court of
competent jurisdiction handling the injunctive relief. Injunctive relief shall
not be the exclusive relief available to the Company, rather it shall be in
addition to any other relief afforded the Company by a court of competent
jurisdiction.

2.10 Termination Rights for Parties. Company shall have the right to terminate
this Agreement in the event Vendor fails to meet the sales requirements set
forth in Section 2.6 of this Agreement. In addition, either party may terminate
this Agreement upon sixty (60) days prior written notice in the event the other
party fails to cure any material breach of its duties and obligations hereunder.

<PAGE>

                                   ARTICLE III

                    REPRESENTATIONS AND WARRANTIES OF COMPANY

          The Company represents and warrants to Vendor as follows:

3.1. Authority of Company.

         The Company has all requisite power and authority to execute and
deliver this Agreement and each other agreement, instrument or document to be
executed by the Company pursuant hereto (collectively the "Related Agreements")
to perform its obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby. This Agreement has been duly
executed and delivered by the Company constitutes the valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms. Upon execution and delivery by the Company, each Related Agreement(s)
will constitute the valid and binding obligation of the Company enforceable
against it in accordance with their terms.

3.2. Organization and Qualification of the Company.

         The Company is duly organized, validity existing and in good standing
under the laws of the state of Utah, and have all requisite power and authority
to own, license and use the Technology and their properties and assets and to
carry on their business as now being conducted.

3.3. No Conflict; Required Filings and Consents.

         (a) This Agreement and the Related Agreements by Company do not, and
the performance of this Agreement and the Related Agreements by Company and the
consummation of the transactions contemplated hereby and thereby will not, (i)
conflict with or violate the articles of organization or operating agreement, in
each case as amended or restated, of Company, (ii) conflict with or violate any
United States federal, state, local or foreign law, statute, ordinance, rule,
regulation, order, judgment or decree applicable to Company or by or to which
any of its properties or assets is bound or subject or (iii) result in any
breach of, or constitute a default (or an event that with notice or lapse of
time or both would constitute a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or require payment
under, or result in the creation of any lien, encumbrance, security interest,
mortgage, pledge, claim, option or restriction of any kind whatsoever
(collectively "Liens") on any of the properties or assets of Company pursuant
to, any agreement, lease, license, contract, note, mortgage, indenture,
arrangement or other obligation ( collectively, "Contracts") to which the
Company is a party or by which any of its properties or assets is bound.

         (b) The execution and delivery of this Agreement and the Related
Agreements by Company do not, and the performance by Company of this Agreement
and the Related Agreements and the consummation of the transactions contemplated
hereby and thereby will not, require the Company to obtain any consent,
approval, authorization or permit of, or to make any filing with or notification
to, any court, administrative agency or commission or other governmental entity,
authority or instrumentality, whether foreign or domestic (a "Governmental
Entity"), or any third party.

3.4. Warranty of Title.

         The Company is the true and lawful owner of, and owns all right, title
and interest in and to, all of the assets used in the Technology, free and clear
of all Liens.

<PAGE>

3.5. Permits.

         The Company possess and shall, at its expense, maintain throughout the
term of this Agreement all FDA and other licenses, permits and other
authorizations from Governmental Entities required by applicable provisions of
laws, ordinances, rules and regulations (collectively, "Permits"), necessary for
the sale and marketing of Sunutra(TM)and the Technology.

3.6. Compliance with Law.

         The Company is in compliance in all material respects with the terms
and conditions of all of the Permits and all laws, rules, regulations and orders
applicable to Company or its Technology in the past five years; and it has not
received any notification that Company or any of its business practices is in
violation of any Permit or any such law, rule, regulation or order.

3.7. No Misleading Statements.

         Neither this Agreement, and Related Agreements nor any certificate or
other document delivered by the Company in connection herewith contains, or will
contain when delivered, any untrue statement of a material fact or omits to
state, or will omit to state when delivered, a material fact necessary in order
to make the statements made herein or therein, in light of the circumstances
under which they were made, not misleading.

3.8. Brokers.

         No broker, finder or investment banker, including any director,
officer, employee, affiliate or associate of the Company, is entitled to any
brokerage, finder's or other fee or commission in connection with the
transactions contemplated by this Agreement based on arrangements made by or on
behalf of the Company or any of their affiliates.

                                   ARTICLE IV

                    REPRESENTATIONS AND WARRANTIES OF VENDOR

          Vendor hereby represents and warrants to the Company as follows:

4.1. Authority.

         Vendor has all requisite power and authority to execute and deliver
this Agreement, to perform its obligations hereunder and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement
by Vendor, the performance of this Agreement by Vendor and the consummation of
the transactions contemplated hereby have been duly authorized and no other
proceeding on the part of Vendor is necessary to authorize this Agreement or to
consummate the transactions contemplated hereby. This Agreement has been duly
executed and delivered by Vendor and constitutes the valid and binding
obligation of Vendor, enforceable against Vendor in accordance with its terms.

4.2. Organization and Qualification of the Vendor.

         The Vendor is duly organized, validity existing and in good standing
under the laws of the state of North Carolina, and have all requisite power and
authority to own, license and use the Technology and their properties and assets
and to carry on their business as now being conducted. The Vendor is, or shall
become duly qualified to do business and in good standing in each jurisdiction
in which the nature of its business or the ownership, licensing or operation of
its assets and business makes such qualification necessary.

<PAGE>

4.3. No Conflict; Required Consents and Approvals.

         (a) The execution and delivery of this Agreement by Vendor do not, and
the performance of this Agreement by Vendor and the consummation of the
transactions contemplated hereby will not, (i) conflict with or violate any
United States federal, state, local or foreign law, statute, ordinance, rule,
regulation, order, judgment or decree applicable to Vendor or by or to which any
of its properties or assets is bound or subject or (ii) result in any breach of,
or constitute a default (or an event that with notice or lapse of time or both
would constitute a default) under any Contracts to which Vendor is a party or by
which any of its properties or assets is bound.

         (b) The execution and delivery of this Agreement by Vendor do not, and
the performance by Vendor of this Agreement and the consummation of the
transactions contemplated hereby will not, require Vendor to obtain any consent,
approval, authorization or permit of, or to make any filing with or notification
to, any court, administrative agency or commission or other Governmental Entity,
or any third party.

4.4. Intellectual Property.

         Vendor acknowledges and agrees that it does not own or possess any
interest in the intellectual property of the Company that is the technology that
is the subject of this Agreement, including, but not limited to the Trademark
name Sunutra(TM), except for any rights thereto granted under this Agreement.
Vendor warrants and covenants that it shall not undertake any action regarding
this technology and trademark unless specifically approved herein, or by other
written agreement executed and delivered to Vendor by the Company. Vendor
covenants that it shall not undertake any act(s) that might infringe upon the
rights of the Company with regard to this technology and/or trademark, and that
it shall immediately inform the Company of any act, action, suit or proceeding
which may infringe and/or affect said rights. Vendor shall not posses, nor shall
it assign or convey any of its rights hereunder without the express written
permission of the Company.

4.5. Permits.

         The Vendor shall obtain and possess and shall, at its expense, maintain
throughout the term of this Agreement all FDA and other licenses, permits and
other authorizations from Governmental Entities required by applicable
provisions of laws, ordinances, rules and regulations (collectively, "Permits"),
necessary for the sale and marketing of Sunutra(TM) and the Technology.

4.6. Compliance with Law.

         The Vendor shall remain and maintain in full compliance in all material
respects with the terms and conditions of all of the Permits and all laws,
rules, regulations and orders applicable to the Vendor as concerns the
Technology.

4.7. Insurance.

         (a) Vendor has provided the Company with a true, correct and complete
list of all products liability and other insurance policies currently held by or
on behalf of Vendor. Such policies are in amounts deemed to be adequate by
Vendor, are sufficient for compliance with all requirements of Governmental
Entities and Contracts to which Vendor is subject. All of such policies are in
full force and effect, all premiums with respect thereto are currently paid and
Vendor has received no notice of cancellation or other notice that any such
policy will not be renewed.

         (b) Vendor has had no loss experience (i) for the current year through
September 30, 2004, and the year ended December 31, 2003, and has no currently
outstanding claims.

         (c) Vendor shall insure and obtain copies of similar insurance policies
from any third party vendors it obtains pursuant to the terms of this Agreement.

<PAGE>

4.8. No Misleading Statements.

         Neither this Agreement, and Related Agreements nor any certificate or
other document delivered by the Vendor in connection herewith contains, or will
contain when delivered, any untrue statement of a material fact or omits to
state, or will omit to state when delivered, a material fact necessary in order
to make the statements made herein or therein, in light of the circumstances
under which they were made, not misleading.

4.9. Brokers.

         No broker, finder or investment banker is entitled to any brokerage,
finder's or other fee or commission in connection with the transactions
contemplated by this Agreement based upon arrangements made by or on behalf of
Vendor; provided, that in the event that Vendor compensates any individual as a
result of this Agreement, Vendor hereby holds Company harmless from and against
any claim(s) of such individual(s).

                                    ARTICLE V

                                 INDEMNIFICATION

5.1. Generally.

         The Company shall indemnify and hold Vendor harmless from and against
any liability, loss, damage, claim, cost or expense (including, without
limitation, expenses of investigation and defense and reasonable fees and
disbursements of counsel), Liens or other obligations of any nature whatsoever
(collectively, "Losses"), incurred by Vendor and arising out of or based upon
(a) any breach by the Company of its representations, warranties, covenants or
agreements set forth in this Agreement or in any document or instrument
delivered by the Company at the closing pursuant hereto; or (b) any claim,
action, suit, proceeding or investigation of any kind, at law or in equity,
arising from a liability of the Company, including, without limitation, any
liability that occurs or exists with respect to the Technology or Intellectual
Property at any time during or after the term of this Agreement.

5.2. Defense or Prosecution of Claims.

         As promptly as practicable after its discovery of grounds for a claim
for indemnification hereunder, Vendor shall deliver a written claim for
indemnification to the Company (the "Indemnifying Party"), specifying in
reasonable detail the basis therefore and, if known, the amount, or an estimate
of the amount, of the Losses arising there from. Thereafter, Vendor shall
provide to Indemnifying Party all information and documentation reasonably
available to it to support and verify such claim. If the facts giving rise to a
claim for indemnification hereunder arise out of the claim of any third party,
or if there is any claim against a third party, Indemnifying Party may, at its
option, assume the defense or the prosecution thereof, with counsel reasonably
satisfactory to Vendor, at the sole cost and expense of Indemnifying Party,
unless (i) such claim seeks an order, injunction or other equitable relief
against Vendor or (ii) Vendor shall have reasonably concluded that there is a
conflict of interest between Indemnifying Party, on the one hand, and Vendor, on
the other hand, in the defense or prosecution of such claim, provided that in
either of such events, Indemnifying Parties may participate in the proceeding.
After any assumption of the defense or prosecution of any claim by Indemnifying
Party, they shall not be liable to Vendor for any legal expenses thereafter
incurred by Vendor. In any such event, whether or not Indemnifying Party do so

<PAGE>

assume the defense or prosecution thereof, Indemnifying Party and Vendor shall
cooperate in the defense or prosecution thereof and shall furnish such records
and information and attend such proceedings as may be reasonably requested in
connection herewith. Indemnifying Party shall have no indemnification
obligations with respect to any claim or demand that is settled by Vendor
without the prior written consent of Indemnifying Party (which consent shall not
be unreasonably withheld), other than any claim or demand as to which Seller
shall not have assumed the defense or prosecution thereof.

5.3. Vendor Indemnity.

         Vendor shall indemnify and hold the Company harmless from Losses
incurred by them and arising out of or based upon any breach by Vendor of its
representations, warranties, covenants or agreements set forth in this Agreement
or in any document or instrument delivered by Vendor in the identical manner and
with the identical rights set forth in paragraphs 5.1. and 5.2. hereinabove as
if said sections had been written with identical language except for the
identity of the respective parties.

                                   ARTICLE VI

                            MISCELLANEOUS AND GENERAL

6.1. Payment of Expenses.

          Each party hereto shall pay its own expenses incident to preparing
for, entering into and carrying out this Agreement and the transactions
contemplated hereby.

6.2. Survival.

         The representations and warranties of the parties herein shall survive
the Closing.

6.3. Entire Agreement; Assignment; Etc.

         This Agreement and the Related Agreements constitute the entire
agreement, and supersede all other agreements, understandings, representations
and warranties, both written and oral, among the parties with respect to the
subject matter hereof, and shall not be assignable by operation of law or
otherwise and are not intended to create any obligations to, or rights in
respect of, any persons other than the parties hereto.

6.4. Captions.

         The Article, Section and paragraph captions herein are for convenience
of reference only, do not constitute part of this Agreement and shall not be
deemed to limit or otherwise affect any of the provisions hereof.

6.5. Severability.

         If any term or other provision of this Agreement, or any portion
thereof, is invalid, illegal or incapable of being enforced by any rule of law
or public policy, all other terms and provisions of this Agreement, or remaining
portion thereof, shall nevertheless remain in full force and effect so long as
the economic or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any party. Upon such determination
that any such term or other provision, or any portion thereof, is invalid,
illegal or incapable of being enforced, the parties hereto shall negotiate in
good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible in an acceptable manner to the end that the
transactions contemplated hereby are consummated to the fullest extent possible.

<PAGE>

6.6. Modification or Amendment.

         The parties hereto may modify or amend this Agreement at any time, only
by a written instrument duly executed and delivered by each party hereto.

6.7. Notices.

         All notices and other communications given or made pursuant hereto
shall be in writing and shall be deemed to have been duly given on the date
delivered, if delivered personally, on the third business day after being mailed
by registered or certified mail (postage prepaid, return receipt requested), in
each case, to the parties at the following addresses: ( or at such other address
for a party as shall be specified by notice given in accordance with this
Section):

         (a)      If to Vendor, to: Nu Specialty Foods Group, LLC Attn: Darryl
                  L. Webb P.O. Box 1179 609 E. Gilbreath Street Graham, North
                  Carolina 27253 Fax: 336-229-0830 email: usfg@bellsouth.net

         (b)      If to Company to: Richard A. Shanks 1455 West Loop South,
                  Suite 200 Houston, Texas 77027 Fax: 832-202-0813 Email:
                  Shanksr@shankspc.com

         No provision of this Agreement, including this Section, shall be deemed
to constitute consent to the manner and address for service of process in
connection with any legal proceeding (including such arising out of or in
connection with this Agreement), which service shall be effected as required by
applicable law.

6.8. Failure or Delay Not Waiver; Remedies Cumulative.

         No failure or delay on the part of any party hereto in the exercise of
any right hereunder shall impair such right or be construed to be a waiver of,
or acquiescence in, any breach of any representation, warranty, covenant or
agreement herein, nor shall any single or partial exercise of any such right
preclude other or further exercise thereof or of any other right. All rights and
remedies existing under this Agreement are cumulative to, and not exclusive of,
any rights or remedies otherwise available.

6.9. Counterparts.

         This Agreement may be executed in the original or by telecopy in any
number of counterparts, each of which shall be deemed to be an original and all
of which together shall constitute one and the same instrument.

6.10. Governing Law.

         This Agreement shall be governed by and construed in accordance with
the law of the State of Texas, without regard to the conflicts of laws
principles thereof.

         IN WITNESS WHEREOF, the parties have executed this Exclusive Marketing
Agreement effective this 1st day of March, 2005.

"Company"                                       "Vendor"

By: /s/ George Mappin                            By: /s/ Darryl L. Webb
   ------------------------------------             --------------------------
   George Mappin                                    Darryl L. Webb
   Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]